Strategy
US Growth Equities
The Driehaus US Growth Equities team focuses on investing in US-listed equities of public companies with market capitalizations between $100 million and $15 billion, through the Driehaus Micro Cap Growth, Driehaus Small Cap Growth, Driehaus Small/Mid Cap Growth and Driehaus Life Sciences strategies. The strategies provide investors with high active share portfolios of companies experiencing positive fundamental change in addition to exposure to positive growth inflections, earnings surprises and earnings revisions, factors that are positively correlated to alpha generation. The team is led by Jeff James who began his portfolio management career at Driehaus in 1998. He is supported by six analysts that combined have over 50 years of Driehaus research experience.
Institutional Investors
Our institutional sales team will be pleased to address questions and requests related to separately managed accounts and/or institutional commingled vehicles that employ our investment strategies.
Ask Us!
Driehaus Micro Cap Growth Strategy
View DetailsDriehaus Micro Cap Growth Strategy
The strategy seeks to outperform the Russell Microcap® Growth Index over full market cycles.
Facts
- Strategy Inception Date
- Jan 01, 1996
- Total Strategy Assets
As of Jun 30, 2019
- $1,147M
Separately Managed Accounts
- Open to New Investors
- No
Funds
Driehaus Small Cap Growth Strategy
View DetailsDriehaus Small Cap Growth Strategy
The strategy seeks to outperform the Russell 2000® Growth Index over full market cycles.
Facts
- Strategy Inception Date
- Jan 01, 1980
- Total Strategy Assets
As of Jun 30, 2019
- $413M
Separately Managed Accounts
- Open to New Investors
- Yes
Funds
Driehaus Small/Mid Cap Growth Strategy
View DetailsDriehaus Small/Mid Cap Growth Strategy
The strategy seeks to outperform the Russell 2500® Growth Index over full market cycles.
Facts
- Strategy Inception Date
- Feb 01, 2012
- Total Strategy Assets
As of Jun 30, 2019
- $40M
Separately Managed Accounts
- Open to New Investors
- Yes
Driehaus Life Sciences Strategy
View DetailsDriehaus Life Sciences Strategy
The strategy intends to exploit the inefficiencies in how markets assign risk to development-stage and early-commercial stage healthcare companies.
Facts
- Strategy Inception Date
- Feb 01, 2019
- Total Strategy Assets
As of Jun 30, 2019
- $29M
Separately Managed Accounts
- Open to New Investors
- Yes
Philosophy & Process
The team employs a growth-oriented investment philosophy focusing on identifying company-specific growth inflection points and exploiting associated marketplace inefficiencies. Core to the philosophy are the beliefs that: earnings are the primary driver of equity prices over time, market expectations tend to be ‘anchored’ to historical information and points of inflection therefore introduce dislocations between market expectations and fundamentals which generate significant alpha capture opportunities. The team combines fundamental, macro/sector/industry and behavioral analysis in its investment process together with a nimble/active investment approach to quickly identify inefficiencies and generate a portfolio, which uniquely seeks to achieve superior aggregate growth rates as well as superior risk characteristics.
Featured Commentary
“Turn Those Machines Back On!”
It has been a rough year for the American farmer. If absorbing the impact of an escalating trade war with China and its adverse impact on crop prices and export volumes was not enough, farmers are now having to contend with Mother Nature. Cold, wet weather and flooding in the spring of 2019 has created a difficult operating environment for farmers.
Druggable Target White Space
The 2002 sequencing of the Human Genome revolutionized our understanding of human disease, giving us heretofore unknown information about the genetic drivers of disease and, by extension, direction on how to address it. This post will provide a snapshot of where we stand in drugging the druggable universe.
View All Commentary